SUBSTRATA MAIN PAGE|
TAXONOMY: Terrabacteria group -> Firmicutes -> Bacilli -> Bacillales -> Bacillaceae -> Bacillus -> Bacillus infantis
B. infantis is organotrophic aerobe that has the ability to metabolize D-xylose, galactose, glucose, fructose, mannitol, sorbitol, methyl a-D-glucoside, N-acetylglucosamine, amygdalin, arbutin, aesculin, salicin, maltose, melibiose, sucrose, trehalose, raffinose, starch, glycogen, gluconate, cellobiose, lactose and inulin. One study predicted the strain NRRL B-14911 to have over 321 possible metabolic pathways and 1088 different participating enzymes. As mentioned previously, the AAA strain of B. infantis has been shown to degrade azo dyes. The hypothalamus-pituitary-adrenal response is involved in the neurobiology of mood disorders and illnesses that include anxiety disorder, bipolar disorder, insomnia, posttraumatic stress disorder, borderline personality disorder, attention deficit-hyperactivity disorder (ADHD), major depressive disorder, burnout, chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, and alcoholism. The normalization of this response, as well as increased angiogenesis, is correlated with increased numbers of Bacillus infantis.
This species has been identified as a resident in the human gastrointestinal tract based on the phylogenetic framework of its small subunit ribosomal RNA gene sequences.[PMC 4262072]
|COGEM||COGEM released a comprehensive database of pathogenicity assessment of around 2575 bacterial species in 2011. The database ranks the pathogenicity of species on a scale of 1 to 4. Bacillus infantis ranks on this scale: |